{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:52:26Z","timestamp":1768423946157,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: MTH1 protects tumor cells and their supporting endothelium from lethal DNA damage triggered by oxidative stress in the tumor microenvironment, thus promoting tumor growth. The impact of MTH1 on the tumor-related immune compartment remains unknown. We hypothesized that MTH1 regulates immune fitness and therefore enhances the activity of currently used immunotherapeutic regimens. Methods: Our hypotheses were validated in two syngeneic murine mesothelioma models using the clinically relevant MTH1 inhibitor, karonudib. We also examined the effect of combined MTH1 and PD-L1 blockade in mesothelioma progression, focusing on the main immune players. Results: Karonudib administration enhances M1 macrophage polarization, stimulates CD8 expansion and promotes the activation of DC and T cells. Combined administration of PD-L1 and MTH1 inhibitors impairs mesothelioma tumor growth and mesothelioma-associated pleural effusion accumulation more effectively compared to each monotherapy. Conclusions: Combined MTH1 and PD-L1 inhibition holds promise for the successful clinical management of mesothelioma.<\/jats:p>","DOI":"10.3390\/cancers15204962","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:46:13Z","timestamp":1697114773000},"page":"4962","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["MTH1 Inhibition Alleviates Immune Suppression and Enhances the Efficacy of Anti-PD-L1 Immunotherapy in Experimental Mesothelioma"],"prefix":"10.3390","volume":"15","author":[{"given":"Sophia F.","family":"Magkouta","sequence":"first","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Photene C.","family":"Vaitsi","sequence":"additional","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianthi P.","family":"Iliopoulou","sequence":"additional","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5763","authenticated-orcid":false,"given":"Apostolos G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7170-2890","authenticated-orcid":false,"given":"Chrysavgi N.","family":"Kosti","sequence":"additional","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherina","family":"Psarra","sequence":"additional","affiliation":[{"name":"Department of Immunology-Histocompatibility, Evangelismos Hospital, 10675 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis T.","family":"Kalomenidis","sequence":"additional","affiliation":[{"name":"\u201cMarianthi Simou Laboratory\u201d, 1st Department of Critical Care and Pulmonary Medicine, Evangelismos Hospital, School of Medicine, National and Kapodistrian University of Athens 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canep.2019.03.014","article-title":"Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study","volume":"60","author":"Bouvier","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/ejcts\/ezx427","article-title":"Predictors of Trimodality Therapy Trends in Therapy for Malignant Pleural mesothelioma","volume":"53","author":"Nelson","year":"2018","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second Line Therapy in Malignant Pleural Mesothelioma: A Systematic Review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1172\/JCI122010","article-title":"DNA repair defects and implications for immunotherapy","volume":"128","author":"Bever","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI86892","article-title":"The host STING pathway at the interface of cancer and immunity","volume":"126","author":"Corrales","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13045-021-01218-8","article-title":"The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e134885","DOI":"10.1172\/jci.insight.134885","article-title":"MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage","volume":"5","author":"Magkouta","year":"2020","journal-title":"JCI Insight"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature13181","article-title":"MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool","volume":"508","author":"Gad","year":"2014","journal-title":"Nature"},{"key":"ref_14","first-page":"14.1.1","article-title":"The isolation and characterization of murine macrophages","volume":"14","author":"Zhang","year":"2008","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Magkouta, S.F., Vaitsi, P.C., Pappas, A.G., Iliopoulou, M., Kosti, C.N., Psarra, K., and Kalomenidis, I.T. (2021). CSF1\/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PD-L1 Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13112546"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e155300","DOI":"10.1172\/jci.insight.155300","article-title":"CSF1\/CSF1R signaling mediates malignant pleural effusion formation","volume":"7","author":"Kosti","year":"2022","journal-title":"JCI Insight"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e003032","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: The tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"624597","DOI":"10.3389\/fimmu.2020.624597","article-title":"The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA","volume":"11","author":"Kumar","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3423","article-title":"Beyond oxidative stress: An immunologist\u2019s guide to reactive oxygen species","volume":"13","author":"Nathan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kotsafti, A., Scarpa, M., Castagliuolo, I., and Scarpa, M. (2020). Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion. Cancers, 12.","DOI":"10.3390\/cancers12071748"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-19-2416","article-title":"Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis","volume":"80","author":"Giurisato","year":"2020","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-00478-8","article-title":"Redox regulation of immunometabolism","volume":"21","author":"Muri","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1535-7163.MCT-19-0437","article-title":"The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors","volume":"19","author":"Samaranayake","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2210836120","DOI":"10.1073\/pnas.2210836120","article-title":"Defining and targeting tumor-associated macrophages in malignant mesothelioma","volume":"120","author":"Wu","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"648687","DOI":"10.3389\/fonc.2021.648687","article-title":"Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(16)32607-7","article-title":"Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers","volume":"69","author":"Yap","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/annonc\/mdu158","article-title":"Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival","volume":"25","author":"Helleday","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","first-page":"e98575","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma","volume":"3","author":"Lee","year":"2018","journal-title":"J. Clin. Investig."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/4962\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:45Z","timestamp":1760130345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/20\/4962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":38,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15204962"],"URL":"https:\/\/doi.org\/10.3390\/cancers15204962","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}